Open access
Open access
Powered by Google Translator Translator

#ESCCongress – RCT: SGLT2 inhibition reduced the combined risk of cardiovascular death or hospitalization in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

29 Aug, 2021 | 18:19h | UTC

Empagliflozin in Heart Failure with a Preserved Ejection Fraction – New England Journal of Medicine

News release: Trial reports first successful results for heart failure with preserved ejection fraction – European Society of Cardiology

Commentary: Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction – EMPEROR-Preserved – American College of Cardiology

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.